298380 — ABL Bio Share News
0.000.00%
Last trade - 00:00- KR₩5tn
- KR₩5tn
- KR₩79bn
Brief: Abl Bio Announces Grabody-B Brain Delivery Platform License Agreement With GSK To Develop Novel Medicines For Neurodegenerative Diseases
Brief: Abl Bio Inc Signs Agreement With Intocell Inc To Use Its Antibody-Drug Conjugate Tech In Product Development
Brief: I-Mab And Abl Bio Announce Latest Updates Of Pd-L1 And 4-1BB Bispecific Antibody TJ-L14B/ABL503
Brief: Abl Bio To Acquire Real Estate Worth 65 Billion Won
Brief: ABL Bio Inc Applies For 1st Phase Clinical Trials For Parkinson's Disease Treatment To U.S. FDA
Brief: ABL Bio Says Entered Into License Agreement With Sanofi To Advance ABL301 For Treatment Of Parkinson's Disease
Brief: ABL Bio Announces Publication Of Preclinical Data Demonstrating Safety And Efficacy Of Abl503/Tj-L14b, A Novel Anti-Pd-L1 X 4-1Bb Bispecific Antibody